EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Botanical Sources: 4

Boswellia Boswellia serrata Roxb.

Also called: Indian frankincense, frankincense, olibanum, boswellia serrata

Boswellia serrata is a tree whose gum resin, known as frankincense or olibanum, is used in Ayurveda. Gum resin extracts are sold as dietary supplements promoted for joint health, mobility and digestion.

Category
Botanical
Part used
Gum resin (oleo-gum resin)
Strongest evidence
B Some positive trials
Native range
Native to the Indian subcontinent
Reviewed
2026-10-28

Class 2 Moderately studied in people. A 2014 Cochrane review of oral herbal therapies for osteoarthritis included five RCTs of three single-herb Boswellia serrata extracts; two of them (85 participants) were pooled. [3]

Fact-checked 2026-10-28 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

5 topics studied5 body areas · strongest grade B

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Boswellia does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Boswellia, evidence grade and finding
Topic studiedGradeWhat the evidence shows
Knee and other osteoarthritis pain and functionBCochrane: two high-quality trials (85 people) of 100 mg/day enriched extract for 90 days cut pain by 17 points (0–100 scale) and improved function by 8 points versus placebo. [3]
Any health condition (overall)CNCCIH: most studies are small and of low quality; there is not enough high-quality evidence to determine whether boswellia is useful for any health condition. [1]
AsthmaCA few small studies suggest oral boswellia may reduce asthma symptoms, but there is not enough rigorous evidence. [1]
Crohn's disease and collagenous colitisCNo significant benefit was found for maintaining remission in Crohn's disease; evidence in collagenous colitis is unclear or negative. [2]
Brain swelling in people with malignant gliomaCIn a small study, oral boswellia may have reduced brain edema (swelling) but not the tumor; larger studies are needed. [1]

Main constituents: Boswellic acids, including 11-keto-beta-boswellic acid (KBA) and 3-acetyl-11-keto-beta-boswellic acid (AKBA); boswellic acid inhibits 5-lipoxygenase in preclinical studies [2]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • 100 mg/day of an enriched Boswellia serrata extract for 90 days in osteoarthritis trials; other single studies used 250 mg or 999 mg daily. [3]

No official upper intake level has been set.

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Score E
    A: well known causeE: unlikely cause

    LiverTox likelihood score E: unlikely cause of clinically apparent liver injury (chapter dated November 4, 2020).

    Details and sources
  • Pregnancy and breastfeeding
    NCCIH: food amounts are likely safe during pregnancy and breastfeeding; little is known about medicinal amounts.

    1 statement in the profile.

    Details and sources
  • Interactions with medicines
    3 listed

    Anticoagulant and antiplatelet drugs; P-glycoprotein substrates; OATP1B3 and MRP2 substrates

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    None on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    Stated

    Health Canada, Joint Health Products, Multiple Ingredient monograph (December 19, 2025), adults 18 and older: Boswellia serrata extract standardized …

    Details and sources
  • Likely safe orally: extract doses up to 1,000 mg daily were used safely in trials lasting up to 6 months, and 2,400 mg for up to 1 month. [1]
  • Food amounts are likely safe in pregnancy and breastfeeding; little is known about medicinal amounts. [1]
  • Generally well tolerated. Case reports include allergic contact dermatitis from topical products and a gastric bezoar after excessive frankincense intake. [2]
Interactions

Interactions

Boswellia
From the table below 3 interactions the sources name. Tap one to read what happens. A line means a documented or possible interaction, not its size.
Known interactions of Boswellia
WithWhat happens
Anticoagulant and antiplatelet drugsBoswellia extracts can inhibit platelet aggregation and may increase bleeding risk; clinical significance has yet to be determined. [2]
P-glycoprotein substratesAn extract and keto-boswellic acids inhibited P-glycoprotein in vitro and may affect drugs it transports; clinical significance is not known. [2]
OATP1B3 and MRP2 substratesKBA and AKBA modulated these transporters in vitro; clinical relevance is not known. [2]

Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.

Quality

Identity, quality and standardization

  • Boswellia should not be confused with guggul or myrrh. [2]
Regulation

Regulatory status

  • US: herbal products for oral use are often marketed as dietary supplements, which, unlike drugs, are not approved by the FDA before sale; manufacturers are responsible for safety and labeling. [1]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Boswellic acids, including 11-keto-β-boswellic acid (KBA) and 3-acetyl-11-keto-β-boswellic acid (AKBA) Pentacyclic triterpene acids [P2]
  • Six boswellic acids characteristic of B. serrata: α-boswellic acid, 3-O-acetyl-α-boswellic acid, β-boswellic acid, 3-O-acetyl-β-boswellic acid, KBA and AKBA Pentacyclic triterpene acids [P4]
  • Essential oils, terpenoids and sugars, prominently pentacyclic triterpene acids such as β-boswellic acid Oleogum resin constituents [P3]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • No NDI notification naming boswellia (Boswellia serrata) or frankincense was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P7]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC evaluation of boswellia (Boswellia serrata) was found (IARC Monographs list of classifications checked 2026-10-29). [P9]
  • No NTP technical report on boswellia (Boswellia serrata) was found (NTP technical reports list checked 2026-10-29). [P10]

Liver (NIH LiverTox)

  • LiverTox likelihood score E: unlikely cause of clinically apparent liver injury (chapter dated November 4, 2020). Boswellia is often in multi-ingredient supplements, some implicated in liver injury, but a specific contribution from boswellia could not be established. [P3]

Interactions with medicines

  • Anticoagulant and antiplatelet drugs: Boswellia extracts can inhibit platelet aggregation and may increase bleeding risk; clinical significance has yet to be determined. [P2]
  • P-glycoprotein substrates: An extract and keto-boswellic acids inhibited P-glycoprotein in vitro and may affect drugs it transports; clinical significance is not known. [P2]
  • OATP1B3 and MRP2 substrates: KBA and AKBA modulated these transporters in vitro; clinical relevance is not known. [P2]

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • BAPP bulletin 'Adulteration of Boswellia serrata' (June 2018): known adulterants are Boswellia frereana, B. sacra (syn. B. carteri), other Boswellia species, Garuga pinnata and Pinaceae (pine-family) resin; replacement with bark or soil has also been reported. Studies found 3 of 17 (18%) and 3 of 7 (43%) commercial products adulterated; one product contained none of the six characteristic boswellic acids. [P4]

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity test or examination of each dietary-ingredient component — US cGMP rule for dietary supplements: at least one appropriate test or examination must verify the identity of any component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)); exemption only through a petition FDA grants (111.75(a)(1)(ii)). [P8]
  • LC-MS profile of the six boswellic acids and the αBA/AαBA and βBA/AβBA ratios — BAPP: B. frereana lacks the six boswellic acids; B. sacra has them in different ratios (about 0.5-0.9 and 0.7-0.8, versus 1.7 and 1.2 in B. serrata, from small sample sets). [P4]
  • Headspace SPME GC-MS volatile profile — BAPP: longifolene- and longipinene-type sesquiterpenes, characteristic of Pinaceae resins, were found in two products labeled B. serrata. [P4]
  • Keto-boswellic acid assay (KBA and AKBA) — Pharmacopeial specifications cited by BAPP: USP requires not less than 1% of the sum of KBA and AKBA (dried basis); the European Pharmacopoeia requires at least 1% KBA and 1% AKBA. [P4]

Supply and conservation

  • Wild-harvested: BAPP (2018) reports that B. serrata oleogum resin is wildcrafted from dry tropical forests in most Indian provinces except Assam and Bengal, with 500-1,000 metric tons harvested in 2008 (Indian Medicinal Plants Database). [P4]
  • Not listed in the CITES Appendices (Species+ status 'NC'). EU: listed in Annex D of the EU wildlife trade regulations through a genus-level listing of Boswellia spp. (Commission Regulation (EU) 2026/1383 of 22 June 2026, effective 29 June 2026), covering live specimens and all parts and derivatives except seeds and pollen and finished products packaged and ready for retail trade. [P6]

Absorption in people

  • No published information found in the sources checked.

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • Health Canada, Joint Health Products, Multiple Ingredient monograph (December 19, 2025), adults 18 and older: Boswellia serrata extract standardized to 40% boswellic acid, 999 mg per day, maximum single dose 333 mg. [P5]

Pregnancy and breastfeeding

  • NCCIH: food amounts are likely safe during pregnancy and breastfeeding; little is known about medicinal amounts. [P1]

Sources for this profile

  1. NCCIH. Boswellia: Usefulness and Safety (Last Updated: April 2025), 2025-04. nccih.nih.gov
  2. Memorial Sloan Kettering Cancer Center. About Herbs: Boswellia (Last Updated September 3, 2026), 2026-09-03. mskcc.org
  3. NIH LiverTox (NIDDK). Boswellia Serrata (last update November 4, 2020). Text read from NCBI's LiverTox archive (livertox_NBK547852, retrieved 2026-10-29)., 2020-11-04. ncbi.nlm.nih.gov
  4. McCutcheon A. Adulteration of Boswellia serrata. Botanical Adulterants Bulletin. ABC-AHP-NCNPR Botanical Adulterants Prevention Program; June 2018, 2018-06. umb.herbalgram.org
  5. Health Canada, NNHPD. Monograph: Joint Health Products, Multiple Ingredient (dated December 19, 2025), 2025-12-19. webprod.hc-sc.gc.ca
  6. CITES/UNEP-WCMC Species+. Boswellia serrata Roxb., taxon concept 99841 (retrieved October 29, 2026), 2026-10-29. speciesplus.net
  7. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  8. eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of October 23, 2026), 2026-10-23. ecfr.gov
  9. IARC Monographs. List of Classifications (retrieved October 29, 2026), 2026-10-29. monographs.iarc.who.int
  10. National Toxicology Program. Technical Reports (list retrieved October 29, 2026), 2026-10-29. ntp.niehs.nih.gov
Sources

Sources

  1. NCCIH. Boswellia: Usefulness and Safety (Last Updated: April 2025), 2025-04. nccih.nih.gov
  2. Memorial Sloan Kettering Cancer Center. About Herbs: Boswellia (Last Updated September 3, 2026), 2026-09-03. mskcc.org
  3. Cameron M, Chrubasik S. Oral herbal therapies for treating osteoarthritis. Cochrane Database Syst Rev 2014;(5):CD002947 (PMID 24848732), 2014-05-22. pubmed.ncbi.nlm.nih.gov
  4. Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data (Govaerts et al., Sci Data 2021). Boswellia serrata Roxb. (accessed 2026-10-28; Kew cannot warrant the accuracy of the data). powo.science.kew.org
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.